KORU's Pivot: New CEO, New Tech, but International Growth Takes a Step Back
Q2 2026 delivered record revenue and a return to profitability, but a strategic retreat on Phesgo and a slower OUS ramp force guidance lower.
KRMD · Earnings Call · 2026-08-05
A New Era, Tempered by International Reality
Adam Kalbermatten stepped into the CEO role this quarter, and his first report was a strong one: revenue rose 18% to $12 million, gross margins expanded nearly 200 basis points above the company's 2026 range, and KORU posted its first positive net income since 2019. As he put it, “This quarter's milestone of returning to positive net income proves our model works.” — Adam Kalbermatten, President and Chief Executive Officer (CEO) · 2026-08-05 Yet the same call brought a sobering cut to full-year guidance, driven almost entirely by the international business. CFO Tom Adams said,
We are narrowing our full year revenue guidance to $47.5 million to $48.5 million... primarily timing related as the broader prefilled conversion story across the rest of Europe continues to move in the right direction.
That caution marks a clear departure from the enthusiasm of just a few months ago. In the Q1 call, Tom had predicted, “Very similar to what we saw last year... we expect to see strength in the back half of the year.” — Tom Adams, Chief Financial Officer · 2026-05-07 Now, management admits the non-tender markets are taking longer to convert. As Adam explained, “It is really about a delay in the timing... the foundational pieces fall into place.” — Adam Kalbermatten, President and Chief Executive Officer (CEO) · 2026-08-05 The market's reaction has been swift: the stock is down nearly 24% over the past 90 days, still in a 30% drawdown from its July high. Notably, prefill conversion — once a top-three momentum keyword — has dropped sharply as a theme, replaced by the more cautious international core growth narrative.
Strategic Pivot: Phesgo Goes, Tech Comes In
The most striking company-specific development is the decision to withdraw the US application for Phesgo. After "productive conversations with the FDA," KORU pivoted toward other oncology molecules that offer "more attractive volume and return on investment." That pivot is captured by a newly resurgent pivot theme. Meanwhile, the company announced the acquisition of a connected monitoring technology asset — a brand-new capability that will enable real-time data insights for patients, pharmacies, and pharma partners. This is a multiyear build, but it positions KORU to move beyond its "highly reliable mechanical device manufacturer" roots toward a digitally enhanced platform.
These moves are bold for a company of this scale (market cap ~$184M). They reflect a deliberate attempt to widen the competitive moat: competitive moat appears in this quarter's keywords for the first time. But the Phesgo withdrawal also shrinks the addressable US oncology opportunity in the near term. Management reassured that the $600k annual US infusions figure previously cited for Phesgo has been removed from their target model, though they remain confident in the broader oncology opportunity internationally.
Secondary Immunodeficiency: The Next Wave
Beyond oncology, KORU is positioning itself for a potentially large new patient population in secondary immunodeficiency (SID). Several pivotal trials are expected to read out over the next 12-18 months, and KORU already has those drugs on label. As Adam noted, “Many of those clinical trials are being done with existing SCIG drugs that Koru already has on label... as soon as the pharmaceutical companies wrap up those clinical trial endpoints, we are really excited about the opportunity to serve more patients.” — Adam Kalbermatten, President and Chief Executive Officer (CEO) · 2026-08-05 This is a fresh strategic theme for the company — secondary immunodeficiency has jumped to the top-five keywords this quarter, up from lower ranks in prior periods. It builds on the core standard of care narrative but targets a distinct, incremental growth driver.
The fundamentals provide a backdrop of steady improvement. Revenue has grown from roughly $8M/year in 2016 to $12M in a single quarter (2026Q1), and gross margin is hovering near 65% on a quarterly basis, though the trailing figure is lower. The balance sheet remains modestly levered, with liabilities at 40.9% of assets. The challenge is that the company is still not consistently profitable — operating income was -$0.86M in Q1, and the Q2 positive net income was a notable milestone but likely wafer-thin.
What Changed and Why It Matters
KORU is at a crossroads. The new CEO is making deliberate, strategic choices: retrenching from a difficult US Phesgo path, investing in connected technology, and positioning ahead of SID and oncology. But the market is punishing the near-term guidance cut and the slower international ramp. The story is now one of a company that is broadening its platform while hitting a speed bump in its most awaited growth driver. The contrast between the durable long-term opportunities and the lumpy near-term execution is what makes this quarter a genuine catalyst for reassessment.“We are successfully transforming KORU from a highly reliable mechanical device manufacturer into a dominant digitally enabled drug delivery platform.” — Adam Kalbermatten, President and Chief Executive Officer (CEO) · 2026-08-05 Investors will need to decide whether that transformation is worth the wait.